Lisata Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: LSTA · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 320017

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Stockholder Vote, Executive Compensation, Equity Plans

TL;DR

<b>Lisata Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 27, 2024, via webcast, with key votes on directors, auditor ratification, and equity plans.</b>

AI Summary

LISATA THERAPEUTICS, INC. (LSTA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Lisata Therapeutics, Inc. will be held on June 27, 2024, at 9:00 a.m. EDT via live webcast. Key voting items include the election of directors and ratification of Grant Thornton LLP as the independent auditor for fiscal year ending December 31, 2024. Stockholders will also vote on amendments to the 2018 Equity Incentive Compensation Plan and the 2017 Employee Stock Purchase Plan. A non-binding advisory vote will be held to approve the compensation of named executive officers. Proxy materials are being furnished to stockholders over the Internet, with a Notice of Internet Availability sent on or about April 29, 2024.

Why It Matters

For investors and stakeholders tracking LISATA THERAPEUTICS, INC., this filing contains several important signals. The meeting will be held virtually, requiring stockholders to access it online, which may impact participation for those less digitally inclined. The company is seeking approval for amendments to its equity incentive and employee stock purchase plans, which could affect future compensation structures and stock dilution.

Risk Assessment

Risk Level: low — LISATA THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.

Analyst Insight

Stockholders should review the proposals regarding director elections, auditor ratification, and amendments to equity plans before the June 27, 2024 meeting.

Key Numbers

Key Players & Entities

FAQ

When did LISATA THERAPEUTICS, INC. file this DEF 14A?

LISATA THERAPEUTICS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by LISATA THERAPEUTICS, INC. (LSTA).

Where can I read the original DEF 14A filing from LISATA THERAPEUTICS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LISATA THERAPEUTICS, INC..

What are the key takeaways from LISATA THERAPEUTICS, INC.'s DEF 14A?

LISATA THERAPEUTICS, INC. filed this DEF 14A on April 29, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Lisata Therapeutics, Inc. will be held on June 27, 2024, at 9:00 a.m. EDT via live webcast.. Key voting items include the election of directors and ratification of Grant Thornton LLP as the independent auditor for fiscal year ending December 31, 2024.. Stockholders will also vote on amendments to the 2018 Equity Incentive Compensation Plan and the 2017 Employee Stock Purchase Plan..

Is LISATA THERAPEUTICS, INC. a risky investment based on this filing?

Based on this DEF 14A, LISATA THERAPEUTICS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.

What should investors do after reading LISATA THERAPEUTICS, INC.'s DEF 14A?

Stockholders should review the proposals regarding director elections, auditor ratification, and amendments to equity plans before the June 27, 2024 meeting. The overall sentiment from this filing is neutral.

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement (This filing type indicates the company is providing its final proxy materials to shareholders for an upcoming meeting.)
Named Executive Officers
Top executives of the company whose compensation is disclosed in proxy statements. (Stockholders will vote on their compensation, making this a key point of interest.)
Independent Registered Public Accounting Firm
A firm hired to audit the company's financial statements. (Ratification of the auditor is a standard agenda item for annual meetings.)

Filing Stats: 4,946 words · 20 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-29 16:51:43

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS 35

SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS 35 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 37

EXECUTIVE COMPENSATION 38

EXECUTIVE COMPENSATION 38 Summary Compensation Table 38 Employment Agreements and Equity Grants 40 Outstanding Equity Awards 41 Pay Versus Performance Disclosure 43 DIRECTOR COMPENSATION 47 EQUITY COMPENSATION PLAN INFORMATION 48 STOCKHOLDER PROPOSALS FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS 49 DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS 49 WHERE YOU CAN FIND ADDITIONAL INFORMATION 49 INFORMATION ON LISATA'S WEBSITE 49 OTHER MATTERS 50 APPENDIX A - 2018 EQUITY INCENTIVE COMPENSATION PLAN, AS AMENDED 51 APPENDIX B - 2017 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED 65 PROXY CARD 73 LISATA THERAPEUTICS, INC. 110 ALLEN ROAD, SECOND FLOOR BASKING RIDGE, NEW JERSEY 07920 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To be Held June 27, 2024 This proxy statement, along with the accompanying notice of 2024 annual meeting of stockholders (the " Annual Meeting "), contains information about the Annual Meeting, including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting at 900 a.m. Eastern Daylight Time. The Annual Meeting will be held via live webcast on the internet. You will be able to participate in the Annual Meeting, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.comLSTA2024. You will not be able to attend the Annual Meeting in person. In this proxy statement, we refer to Lisata Therapeutics, Inc. as " Lisata ," " the Company ," " we " and " us ." This proxy statement relates to the solicitation of proxies by our Board of Directors for use at the Annual Meeting. On or about April 29, 2024, we will begin sending the Important Notice Regarding the Availability of Proxy Materials to all stockholders entitled to vote at the Annual Meeting. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 27, 2024 This proxy statement and our 2023 annual report to stockholder

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing